Personalized therapeutics of α1-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
Ling-ling Zhu,1 Zhi-jun Feng,2 Quan Zhou3 1Geriatric VIP Ward, Division of Nursing, 2Department of Urology Surgery, 3Department of Pharmacy, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China We read with great i...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/6db82784acbc448ab65276f3af05e013 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Ling-ling Zhu,1 Zhi-jun Feng,2 Quan Zhou3 1Geriatric VIP Ward, Division of Nursing, 2Department of Urology Surgery, 3Department of Pharmacy, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China We read with great interest the multicenter, prospective, comparative cohort study by Zhang et al1 who suggested that patients with uncontrolled or untreated hypertension and lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH/LUTS) should be warned about a decrease in blood pressure on initiation of alfuzosin 10 mg therapy alone or concomitantly with antihypertensive medication. Here we discuss and share our perspectives on this issue. View original paper by Zhang and colleagues. |
|---|